Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034454495> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2034454495 endingPage "251" @default.
- W2034454495 startingPage "247" @default.
- W2034454495 abstract "Amyotrophic lateral sclerosis (ALS) is a rare disease involving selective and progressive degeneration and disappearance of motor neurons. Oxidative stress is believed to contribute to its pathogenesis. We have investigated the efficacy and safety of edaravone, a free radical scavenger previously approved for treatment of acute cerebral infarction, in ALS patients. Within an open trial design, 20 subjects with ALS received either 30 mg (5 subjects) or 60 mg (15 subjects) of edaravone via intravenous drip once per day. Two weeks of administration was followed by a two‐week observation period. This four‐week cycle was repeated six times. The primary endpoint was the change in the revised ALS functional rating scale (ALSFRS‐R) score, while the secondary endpoint was 3‐nitrotyrosine (3NT) level in cerebrospinal fluid (CSF). Efficacy was evaluated in the 60 mg group. During the six‐month treatment period, the decline in the ALSFRS‐R score (2.3±3.6 points) was significantly less than that in the six months prior to edaravone administration (4.7±2.1 points); the difference between the two was 2.4±3.5 points (Wilcoxon signed rank test, p = 0.039). In almost all patients, CSF 3NT, a marker for oxidative stress, was markedly reduced to almost undetectable levels at the end of the six‐month treatment period. Data from the present study suggest that edaravone is safe and may delay the progression of functional motor disturbances by reducing oxidative stress in ALS patients." @default.
- W2034454495 created "2016-06-24" @default.
- W2034454495 creator A5008632411 @default.
- W2034454495 creator A5038009551 @default.
- W2034454495 date "2006-01-01" @default.
- W2034454495 modified "2023-10-16" @default.
- W2034454495 title "Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)" @default.
- W2034454495 cites W1561516473 @default.
- W2034454495 cites W1977069725 @default.
- W2034454495 cites W1992112631 @default.
- W2034454495 cites W1994746821 @default.
- W2034454495 cites W2030654136 @default.
- W2034454495 cites W2055317912 @default.
- W2034454495 cites W2056123940 @default.
- W2034454495 cites W2082174518 @default.
- W2034454495 cites W2085165928 @default.
- W2034454495 cites W2096386031 @default.
- W2034454495 cites W2108381339 @default.
- W2034454495 cites W2158719727 @default.
- W2034454495 cites W2188308812 @default.
- W2034454495 cites W2314689571 @default.
- W2034454495 cites W2411138595 @default.
- W2034454495 cites W2910714656 @default.
- W2034454495 cites W4237126259 @default.
- W2034454495 cites W4240083082 @default.
- W2034454495 cites W4244605837 @default.
- W2034454495 cites W92741982 @default.
- W2034454495 doi "https://doi.org/10.1080/17482960600881870" @default.
- W2034454495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17127563" @default.
- W2034454495 hasPublicationYear "2006" @default.
- W2034454495 type Work @default.
- W2034454495 sameAs 2034454495 @default.
- W2034454495 citedByCount "206" @default.
- W2034454495 countsByYear W20344544952012 @default.
- W2034454495 countsByYear W20344544952013 @default.
- W2034454495 countsByYear W20344544952014 @default.
- W2034454495 countsByYear W20344544952015 @default.
- W2034454495 countsByYear W20344544952016 @default.
- W2034454495 countsByYear W20344544952017 @default.
- W2034454495 countsByYear W20344544952018 @default.
- W2034454495 countsByYear W20344544952019 @default.
- W2034454495 countsByYear W20344544952020 @default.
- W2034454495 countsByYear W20344544952021 @default.
- W2034454495 countsByYear W20344544952022 @default.
- W2034454495 countsByYear W20344544952023 @default.
- W2034454495 crossrefType "journal-article" @default.
- W2034454495 hasAuthorship W2034454495A5008632411 @default.
- W2034454495 hasAuthorship W2034454495A5038009551 @default.
- W2034454495 hasConcept C126322002 @default.
- W2034454495 hasConcept C203092338 @default.
- W2034454495 hasConcept C2776151105 @default.
- W2034454495 hasConcept C2779134260 @default.
- W2034454495 hasConcept C2779554857 @default.
- W2034454495 hasConcept C2780596555 @default.
- W2034454495 hasConcept C2992339995 @default.
- W2034454495 hasConcept C42219234 @default.
- W2034454495 hasConcept C535046627 @default.
- W2034454495 hasConcept C71924100 @default.
- W2034454495 hasConceptScore W2034454495C126322002 @default.
- W2034454495 hasConceptScore W2034454495C203092338 @default.
- W2034454495 hasConceptScore W2034454495C2776151105 @default.
- W2034454495 hasConceptScore W2034454495C2779134260 @default.
- W2034454495 hasConceptScore W2034454495C2779554857 @default.
- W2034454495 hasConceptScore W2034454495C2780596555 @default.
- W2034454495 hasConceptScore W2034454495C2992339995 @default.
- W2034454495 hasConceptScore W2034454495C42219234 @default.
- W2034454495 hasConceptScore W2034454495C535046627 @default.
- W2034454495 hasConceptScore W2034454495C71924100 @default.
- W2034454495 hasIssue "4" @default.
- W2034454495 hasLocation W20344544951 @default.
- W2034454495 hasLocation W20344544952 @default.
- W2034454495 hasOpenAccess W2034454495 @default.
- W2034454495 hasPrimaryLocation W20344544951 @default.
- W2034454495 hasRelatedWork W2327025416 @default.
- W2034454495 hasRelatedWork W2360014013 @default.
- W2034454495 hasRelatedWork W2365126316 @default.
- W2034454495 hasRelatedWork W2369870901 @default.
- W2034454495 hasRelatedWork W2383963979 @default.
- W2034454495 hasRelatedWork W2391069285 @default.
- W2034454495 hasRelatedWork W2903898378 @default.
- W2034454495 hasRelatedWork W3031559472 @default.
- W2034454495 hasRelatedWork W88464185 @default.
- W2034454495 hasRelatedWork W3030072676 @default.
- W2034454495 hasVolume "7" @default.
- W2034454495 isParatext "false" @default.
- W2034454495 isRetracted "false" @default.
- W2034454495 magId "2034454495" @default.
- W2034454495 workType "article" @default.